{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T17:40:26Z","timestamp":1734370826381,"version":"3.30.2"},"reference-count":10,"publisher":"SLACK, Inc.","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>This report aims to describe the clinical presentation of a patient with an atypical central retinal vein occlusion (CRVO) in the setting of multiple myeloma. The patient was a 72-year-old man with an extensive hematologic-oncologic history and cardiovascular risk factors who presented with new-onset blurry vision and visual acuity (VA) of 20\/40 in the left eye. The VA worsened to 20\/60 two months after the initial presentation. By the 6-month follow-up visit, a series of three intravitreal bevacizumab injections for macular edema improved VA from 20\/60 to 20\/40. This case demonstrates the importance of fluorescein angiography in diagnosing a CRVO and exemplifies an atypical presentation on exam and imaging studies.<\/jats:p>\n          <jats:p>\n            <jats:bold>\n              [\n              <jats:italic>Ophthalmic Surg Lasers Imaging Retina<\/jats:italic>\n              2024;55:730\u2013733.]\n            <\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/23258160-20240718-02","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T15:12:16Z","timestamp":1724339536000},"page":"730-733","source":"Crossref","is-referenced-by-count":0,"title":["Atypical Central Retinal Vein Occlusion in an Older Man With Multiple Myeloma: A Case Report"],"prefix":"10.3928","volume":"55","author":[{"given":"Matthew J.","family":"Finn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.22608\/APO.2017442"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/724780"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.4314\/wajm.v26i4.28324"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/cxo.12319"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2012.11.002"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.5811\/1\/cpcem.2022.4.55710"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-015-0056-8"},{"key":"e_1_3_1_10_2","unstructured":"United States Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) public dashboard. Updated December 7 2023. Accessed July 30 2024. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000514695"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T17:06:38Z","timestamp":1734368798000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20240718-02"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":10,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.3928\/23258160-20240718-02"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20240718-02","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"type":"print","value":"2325-8160"},{"type":"electronic","value":"2325-8179"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}